Skip to search formSkip to main contentSkip to account menu

BMY 28100

Known as: BMY-28100 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
The objective of this Phase I study was to evaluate the safety, tolerance, and pharmacokinetics of BMY-28100 in 36 male subjects… 
1990
1990
General pharmacological properties of BMY-28100, a new semisynthetic oral cephalosporin, were studied in experimental animals… 
1990
1990
Twenty pediatric patients (ages, between 8 months and 8 years) received a single oral dose of cefprozil at levels of 15 and 30 mg… 
1988
1988
BMY-28100 is a new orally absorbed cephalosporin whose in vitro activity was compared with that of cefaclor. BMY-28100 was more… 
1987
1987
The antibacterial activity of BMY-28100, a new oral cephalosporin, was measured against 300 bacterial isolates from pediatric… 
1987
1987
The synthesis and structure-activity relationships of 7-[D-alpha-amino-alpha-(4-hydroxyphenyl)-acetamido]-3-[(Z)-1-propenyl]- 3… 
1987
1987
A new semisynthetic oral cephalosporin, BMY-28100, was evaluated for in vitro and in vivo antibacterial activities in comparison… 
1987
1987
Using a broth microdilution method, the in vitro activity of BMY-28100 against 365 clinical strains of commonly isolated bacteria… 
1987
1987
The BMY-28100 30-micrograms-disk test was evaluated by using 615 clinical isolates. Regression analyses and error rates were… 
1987
1987
BMY-28100 was compared with cephalexin, cefaclor, cefixime, and cefteram and found to be more active than the reference…